Celgene-Backed Antengene Climbs On Hong Kong Debut

Shares in Antengene, a clinical-stage pharmaceuticals business, gained 1.1% from their IPO price on their debut at the Hong Kong Stock Exchange on Friday, closing at HK$18.28. Antengene is focused on …